The Dual Effects of CDK4/6 Inhibitors on Tumor Immunity.

Cancers (Basel) · 2025 · PMC12730504 · PMID 41463246

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

From the clinical trials of CDK4/6is combined with immune checkpoint inhibitors (ICI), only the PACE study reported prolonged PFS with fulvestrant, palbociclib and avelumab in patients whose disease progressed after CDK4/6is + AI, although this improvement did not reach statistical significance and the regimen was relatively well tolerated [ 112 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.